Who Paid My Doc
Harrison Tsai
Molecular Genetic Pathology Boston, MA Medical Doctor
NPI 1164845343 CMS profile 2067788
300 Longwood Ave, Boston, MA 02115
General payments
$3,563
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Harrison Tsai of Boston, MA is reported in the CMS Open Payments database as having received $3,563 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $3,563 | 2 |
Beside peers
- Harrison Tsai
- Molecular Genetic Pathology median
- Middle half of Molecular Genetic Pathology
- National median
In program year 2025, general payments to Harrison Tsai were reported at $0. Among 27 Molecular Genetic Pathology profiles paid that year, the median was $225 and the middle half received between $91 and $3,596.
Show as a table
| Year | Harrison Tsai | Molecular Genetic Pathology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $131 | $38–$1,524 | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | $900 | $25–$1,899 | $132 |
| 2022 | $3,563 | $136 | $28–$4,738 | $149 |
| 2023 | $0 | $139 | $48–$3,150 | $160 |
| 2024 | $0 | $1,077 | $71–$2,833 | $164 |
| 2025 | $0 | $225 | $91–$3,596 | $169 |
Breakdown
Billing to Medicare
Part B · data year 2024 · 2 billing codesPaid by Medicare
$18,016
Medicare patients
443
Services billed
494
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 46% | |
| Ischemic heart disease | 34% | |
| Chronic kidney disease | 34% | |
| Atrial fibrillation | 31% | |
| Diabetes | 25% | |
| Heart failure | 24% | |
| Depression | 24% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Molecular Genetic Pathology in Massachusetts
Related records
Molecular Genetic Pathology in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Molecular Genetic Pathology
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.